Details

Autor(en) / Beteiligte

• Salazar, Juliana
• Moya, Patricia
• Altés, Albert
• Díaz-Torné, César
• Casademont, Jordi
• Cerdà-Gabaroi, Dacia
• Corominas, Hèctor
• Baiget, Montserrat

Titel

Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?

Ist Teil von

• Pharmacogenomics, 2014-06, Vol.15 (8), p.1079-1090

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Methotrexate (MTX) is the first-line treatment option for newly diagnosed rheumatoid arthritis (RA) patients. However, 50-70% of the patients respond to treatment and 30% suffer toxicity. : To identify pharmacogenetic markers of outcome in RA patients treated with MTX. We analyzed 27 genetic variants in , , , and genes. We included 124 RA patients treated with MTX monotherapy. In multivariate analyses two variants in the gene were associated with response, rs17421511 (p = 0.024) and rs1476413 (p = 0.0086), as well as one in the gene, rs1643650 (p = 0.026). The rs16853826 variant was associated with toxicity (p = 0.039). , and genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under MTX monotherapy. Original submitted 10 January 2014; Revision submitted 28 March 2014